OptimizeRx Reports First Quarter 2019 Results; Total Revenue Up 27% to $5.2 Million, Driving Non-GAAP Net Income up 130% to $833,000 or $0.06 per Diluted Share
Q1 2019 Financial Highlights
- Total revenue increased 27% to
- Gross margin improved from 51.2% to 69.6%.
- Net income of
$7,000vs. a loss of $189,000.
- Non-GAAP net income up 130% to
$833,000or $0.06per diluted share (see definition of non-GAAP measures and reconciliation to GAAP, below).
Q1 2019 Operational Highlights
- Integrated with healthcare industry’s leading acute electronic health record (EHR) systems, including Epic and
- Partnered with IllumiCare, a pioneer in point-of-care healthcare information technology that saves hospitals millions annually. IllumiCare's Smart Ribbon® platform will feature OptimizeRx’s new RxSavings App that delivers drug savings opportunities to providers and patients at the point-of-care.
- Formed OptimizeMDs, a multi-specialty physician panel with the mission of improving the effectiveness of digital health communications delivered throughout the care continuum.
Q1 2019 Financial Summary
Total revenue in the first quarter of 2019 increased 27% to
Gross margin improved to 69.6% in the first quarter of 2019 from 51.2% in the year-ago quarter. The improvement was due to a favorable shift in product mix. The company expects to maintain gross margins of at least 60% on a quarterly basis in 2019.
Operating expenses totaled
Net income on a GAAP basis in the first quarter of 2019 was
Non-GAAP net income for the first quarter of 2019 was up 130% to
The company expects to remain GAAP profitable on a quarterly basis. Although one-time expenses related to investments in growth initiatives could result in a loss in any given quarter.
Cash and cash equivalents totaled
“In Q1, we realized our eighth quarter in a row of revenue growth, along with record gross margin and continued profitability,” said
“While we saw strong topline growth in Q1, our penetration into pharma remains relatively low. We’re connected to many manufacturers, but we’ve really only just begun to penetrate the market. We see a lot of growth ahead of us and to manage this anticipated growth, we recently appointed Stephen Silvestro to the new position of chief commercialization officer. He brings a depth of knowledge and a shared determination to provide affordability and adherence solutions that link the health care and life sciences industries. We’ve reached a scale where we can better negotiate enterprise pricing and he will help in this area.
“OptimizeRx’s technical integration with Epic and
Febbo added: “With the growth of both our pharmaceutical products and our distribution network, we expect that our financial, brand, and clinical messaging to continue to grow throughout the year, along with our increasing patient engagement activities. All of this is expected to drive another year of record growth, with strong margins and profitability.”
Toll-free dial-in number: 1-888-224-1005
International dial-in number: 1-323-994-2093
Conference ID: 3593483
Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact CMA at 1-949-432-7566.
A replay of the call will be available after
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 3593483
Definition and Use of Non-GAAP Financial Measures
This earnings release includes a presentation of non-GAAP net income (loss) and non-GAAP earnings per share or non-GAAP EPS, both of which are non-GAAP financial measures. The company defines non-GAAP net income (loss) as GAAP net income (loss) with an adjustment to add back depreciation, amortization and stock-based compensation expense. Non-GAAP EPS is defined as non-GAAP net income (loss) divided by the number of weighted average shares outstanding on a basic and diluted basis. We have provided non-GAAP financial measures to aid investors in better understanding our performance. Management believes that these non-GAAP financial measures provide additional insight into the operations and cashflow of the Company.
Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash operating expenses, management believes that providing non-GAAP financial measures that excludes non-cash expenses allows for meaningful comparisons between the company’s core business operating results and those of other companies, as well as provides an important tool for financial and operational decision making and for evaluating the company’s own core business operating results over different periods of time.
The company’s non-GAAP net income (loss) and non-GAAP EPS measures may not provide information that is directly comparable to that provided by other companies in the company’s industry, as other companies in the industry may calculate such non-GAAP financial results differently. The company’s non-GAAP net income (loss) and non-GAAP EPS are not measurements of financial performance under GAAP and should not be considered as an alternative to operating income or as an indication of operating performance or any other measure of performance derived in accordance with GAAP. The company does consider these non-GAAP measures to be substitutes for or superior to the information provided by its GAAP financial results.
The table, “Reconciliation of non-GAAP to GAAP Financial Measures,” included at the end of this press release provides a reconciliation of non-GAAP net income (loss) and non-GAAP EPS for the three month periods ended
The cloud-based solution supports patient adherence to medications and better healthcare outcomes with real-time access to financial assistance, prior authorization, education and critical clinical information. OptimizeRx provides more than half of the ambulatory patient market with access to these benefits through leading EHR platforms like Allscripts, Amazing Charts and Quest, and directly via its mobile communications platform.
For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONDENSED CONSOLIDATED BALANCE SHEETS
|Cash and cash equivalents||$||10,133,940||$||8,914,034|
|Total Current Assets||15,482,850||15,732,021|
|Property and equipment, net||146,543||149,330|
|Patent rights, net||2,712,855||2,766,944|
|Other intangible assets, net||2,397,791||2,492,123|
|Right of use assets, net||644,335||-|
|Other assets and deposits||193,972||235,647|
|Total Other Assets||9,627,466||9,173,227|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Accounts payable – trade||$||584,820||$||411,010|
|Revenue share payable||1,132,102||1,908,616|
|Current portion of lease obligations||110,065||-|
|Current portion of contingent purchase price payable||1,092,000||-|
|Total Current Liabilities||3,856,267||4,231,133|
|Lease obligations, net of current portion||537,716||-|
|Contingent purchase price payable, net of current portion||1,421,000||2,365,000|
|Total Non-current liabilities||1,958,716||2,365,000|
|Commitments and contingencies||-||-|
|Preferred stock, $0.001 par value, 10,000,000 shares authorized, no issued and outstanding at March 31, 2019 or December 31, 2018||-||-|
|Common stock, $0.001 par value, 500,000,000 shares authorized, 12,278,833 and 12,038,618 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively||12,279||12,039|
|Total Stockholders’ Equity||19,441,876||18,458,445|
|TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY||$||25,256,859||$||25,054,578|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
|For the Three Months|
|Ended March 31,|
|COST OF REVENUES||1,583,480||2,008,092|
|INCOME (LOSS) FROM OPERATIONS||132,165||(191,196||)|
|OTHER INCOME (EXPENSE)|
|Change in Fair Value of Contingent Consideration||(148,000||)||-|
|TOTAL OTHER INCOME (EXPENSE)||(125,636||)||2,017|
|INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES||6,529||(189,179||)|
|PROVISION FOR INCOME TAXES||-||-|
|NET INCOME (LOSS)||$||6,529||$||(189,179||)|
|WEIGHTED AVERAGE SHARES OUTSTANDING|
|NET LOSS PER SHARE|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
|For the Three Months
Ended March 31,
|CASH FLOWS FROM OPERATING ACTIVITIES:|
|Net Income (loss)||$||6,529||$||(189,179||)|
|Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:|
|Depreciation and amortization||190,301||54,473|
|Stock issued for services||106,034||28,875|
|Change in fair value of contingent consideration||148,000||-|
|Prepaid expenses and other assets||(44,201||)||64,015|
|Revenue share payable||(776,514||)||(279,328||)|
|Accrued expenses and other liabilities||(1,034,454||)||(404,291||)|
|NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES||889,969||(787,388||)|
|CASH FLOWS USED IN INVESTING ACTIVITIES:|
|Purchase of equipment||(13,848||)||(3,803||)|
|NET CASH USED IN INVESTING ACTIVITIES||(13,848||)||(36,566||)|
|CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:|
|Proceeds from exercise of stock options||343,785||-|
|NET CASH PROVIDED BY FINANCING ACTIVITIES||343,785||-|
|NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS||1,219,906||(823,954||)|
|CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD||8,914,034||5,122,573|
|CASH AND CASH EQUIVALENTS - END OF PERIOD||$||10,133,940||$||4,298,619|
|SUPPLEMENTAL CASH FLOW INFORMATION:|
|Cash paid for interest||$||-||$||-|
|Cash paid for income taxes||$||-||$||-|
|Non-cash effect of issuance of shares related to net settled options||$||-||$||-|
|Non-cash effect of cumulative adjustments to accumulated deficit||$||3,229||$||142,027|
|Lease liabilities arising from right of use assets||$||672,809||$||-|
|Non-cash issuance of shares to WPP, plc||$||-||$||447,000|
Reconciliation of non-GAAP to GAAP Financial Measures
|For the Three Months
Ended March 31,
|Net income (loss)||$||6,529||$||(189,179||)|
|Depreciation and amortization||190,501||54,473|
|Non-GAAP net income (loss)||$||833,376||$||362,416|
|Non-GAAP net income (loss) per share|
|Weighted average shares outstanding:|
Tel (248) 651-6568 x807
Media Relations Contact
Tel (860) 800-2344
Investor Relations Contact
Tel (949) 432-7557
Source: OptimizeRx Corporation